A method for reducing electrode gap distances in an electronic device having a first electrode spatially separated from a second electrode by an electrode gap can comprise selecting (810) a milometer gap size to bind a biological material based on a size of the biological material and binding effects with the biological material. The method can further comprise coating (820) at least one surface of an electrode gap region with a first layer including molecular recognition groups, and coating (830) the at least one surface with a second layer including electrically-conductive solids that are configured to bond with the molecular recognition groups. The electronic device can be further coated (840) with additional alternating layers of the molecular recognition groups and the electrically-conductive solids to reach the nanometer gap size between a first electrode and a second electrode of the electronic device.

The present invention provides an immunodiagnostic test device for the detection of anti-dengue virus antibodies comprising a first dengue antigen and a second dengue antigen, wherein the first dengue antigen comprises a polypeptide having at least 90% sequence identity to SEQ ID NO. 1 and the second dengue antigen comprises a polypeptide having the sequence of SEQ ID NO. 2 or a polypeptide having a sequence which has at least 1 and no more than 4 amino acid substitutions with respect to the sequence of SEQ ID NO. 2.

The present application relates to composition of matter, processes and use of composition of matter relating to flavivirus peptides and epitopes, for example, for therapeutic or preventative vaccination against a flavivirus, and/or for inducing, enhancing, or sustaining an immune response against a flavivirus, and/or for detecting an infection with or an exposure to a flavivirus in a subject. The flavivirus may be for example the Zika and/or Dengue virus.

A method for providing variable function medical tests, comprising providing by a mobile device application a plurality of selectable medical test functions, receiving information from the mobile device application regarding test results from a test performed using a testing device, wherein the testing device includes an alignment target disposed on the testing device and a plurality of immunoassay test strips receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing by the server the single value to a control value stored on the server, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting FcγRIIA or FcγRIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans.

A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.

A visibly perceived colorimetric pathogen sensor (100) can comprise a substrate (110) and an molecular recognition group (120) coupled to the substrate (110). The molecular recognition group (120) can be operable to bind to a target pathogen (130). Upon the molecular recognition group (120) binding with the target pathogen (130), reflected light can be altered thereby changing apparent color.

Technologies are described for detecting a pathogen. An example system can include a sensor array (118) having a plurality of sensors that include virus sensors (112) which directly detect a whole vims and at least one of a biomarker sensor, antibody sensor, saturated oxygen sensor, temperature sensor, and heart rate sensor (114a-114n). The system also includes executable instructions that receive sensor output from at least a portion of sensors included in the sensor array (118), assign weights to the sensor output of individual sensors in the sensor array based (118) in part on characteristics of the individual sensors to detect the response signature associated with the pathogen, and determine whether the pathogen has been detected based on the weights assigned to the sensor output of the individual sensors. The system can output (124) an indication whether the pathogen has been detected.

The present invention relates to a method of elevating prediction accuracy of grouping subjects with severe dengue infection. In the method, a non-structural protein 1 (NS1) and an endogenous anti-NS1 antibody of dengue virus in an ex vivo biological specimen are detected and crossly compared, leading in reduce of false negative rates of testing results, as well as elevating grouping accuracy of patients with severe dengue infection.

The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 β-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.